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Abstract
Clear cell carcinoma of the bladder is a rare tumor of the bladder. There are few reports available on this rare
disease, and no cases with recurrence were reported. Here we present a case of 68-year-old woman with primary
clear cell carcinoma of the bladder, who underwent repeat TUR-BT and tumor recurrence. We also reviewed the
previous treatments and prognoses in previous case reports and evaluate the proper treatment for this disease.
Once the diagnosis is determined, the radical surgery should be recommended. The recurrence is not prevented
based on post-TUR intravesical therapy.
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Background
Bladder cancer is the most common malignancy of the
urinary tract, and the 9th most common cancer diagno-
sis worldwide, with more than 330,000 new cases each
year and more than 130,000 deaths per year. Its gener-
ally estimated male:female incidence ratio is 3.8:1.0 [1].
At any point in time 2.7 million people have a history of
urinary bladder cancer [1]. The histological and patholo-
gical type of bladder cancer is mainly urothelial carci-
noma, also called transitional cell carcinoma, accounting
for approximately 90%[2]. Other types including squa-
mous cell carcinoma and adenocarcinoma, account for
3-7% and < 2% respectively [3]. Based on the definition
of WHO, bladder adenocarcinoma is a malignant neo-
plasm derived from the urothelium showing histologi-
cally pure glandular phenotype [4]. Clear cell type is one
of its histological growth patterns. Other patterns
include enteric (colonic) type, adenocarcinoma not
otherwise specified (NOS), signet ring cell, mucinous
(colloid), hepatoid and mixed [4]. As an extremely rare
variant of adenocarcinoma, clear cell type affects women
more often than men. There are few reports available
on this rare disease, and no cases with recurrence were
reported. In the present report, a case of clear cell carci-
noma of the bladder with repeat recurrence is presented.
The purpose of our article is to add an additional case
to the literature, to review the literature, and to formu-
late treatment recommendations.
Case Presentation
A 68-year-old female was admitted to our department
with 1-year history of dysuria and painful urination. The
symptoms were partially relieved after antibiotic therapy,
but had become worse in the previous 2 months,
accompanied by urinary frequency and urgency. No
positive physical signs were found. HGB in blood was
98 g/L. Routine urinalysis showed that RBC in urine
was 210.80/ul and WBC in urine was 4277.40/ul. Other
routine test results were normal. Ultrasonography
demonstrated a 6.0 cm × 7.4 cm mass with low-level
echo in the bladder, with an irregular shape and rich
blood supply. On CT the inferior and posterior wall had
become thickened and from which a 6.4 cm × 7.4 cm
mass protruded into the bladder cavity and the urethra.
CT also showed that the mass did not invade into the
uterus and no pelvic lymphadenopathy was detected.
(Figure 1). Cystoscopy demonstrated a mass measuring
about 6 cm in maximum diameter with cauliflower-like
surface located in the right lateral wall and extending to
the internal urethral orifice. The right ureteric orifice
* Correspondence: cqh2988@126.com
1Department of Urology, The First Hospital of Jilin University, Changchun,
China
Full list of author information is available at the end of the article
Lu et al. World Journal of Surgical Oncology 2012, 10:33
http://www.wjso.com/content/10/1/33 WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
© 2012 Lu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
was invisible. The patient was diagnosed with bladder
cancer, urinary tract infection and anemia. The tumoral
mass was resected by means of transurethral resection
(TUR) and all visible masses were completely resected.
On gross examination, the TUR tissue was fragmented
and grayish white, and its texture was soft. Microscopi-
cally, most of the tumor cells were arranged in tubular
glands, microcysts or fine papillae, partly in diffuse
sheets or solid nests (Figure 2). The tubular glands and
microcysts had different sizes and irregular shapes,
which included eosinophilic and/or basophilous secre-
tions (Figure 3). Most tumor cells were in cuboidal or
columnar shape and hobnail cells were seen containing
abundant clear cytoplasm (Figure 4). The pathological
diagnosis was clear cell adenocarcinoma of the bladder.
The muscular layer of the bladder was invaded by
tumor cells. The immunohistochemical staining reveals
CK7(+), CK20(+), CA125(+) and EMA(+), while PR(-),
ER(-), CD10(-) and HMB(-). (Anti-CK7, Abcam, mouse
monoclonal; anti-CK20, Santa Cruz, mouse monoclonal;
anti-CA125, Abbiotec, rabbit polyclonal; anti-EMA,
Pierce, mouse monoclonal; anti-PR, Santa Cruz, rabbit
polyclonal; anti-ER, Santa Cruz, mouse monoclonal;
anti-CD10, Abcam, mouse monoclonal; anti-HMB,
Dako, mouse monoclonal)
Based on preoperative examination and postoperative
pathological diagnosis, we determined clinical TNM
stage as T2aN0M0. Postoperatively, we suggest the
patient should undergo radical cystectomy. But the
patient refused any partial or radical cystectomy sur-
geries or possible urinary diversion strongly. Then we
suggested the patient try chemotherapy or radiother-
apy, but the patient was still afraid of side effects and
insisted receiving intravesical therapy, which is a classi-
cal postoperative treatment to prevent recurrence for
transitional cell carcinoma of bladder. The
Figure 1 CT showed a tumor at posterior wall of the bladder
which has not invaded the perivesical spaces and uterus.
Figure 2 Tumour cells were arranged in tubular gland,
microcysts or fine papillary in most area, partly in diffuse
sheets or solid nests.
Figure 3 Tubular glands and microcysts have different sizes
and irregular shapes with eosinophilic and/or basophilic
secretions.
Figure 4 Tumor cells were in cuboidal, columnar or hobnail
shape, with abundant clear cytoplasm.
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postoperative therapy was mitomycin, 20 mg, once per
week for 2 months. At first the patient’s urinary symp-
toms have been relieved postoperatively. However,
three months after the surgery, a recurrent tumor was
found by cystoscopy. A sessile mass was found at the
internal urethral orifice, located at 1-3 o’clock and 7-
11 o’clock of the vesical neck through cystoscopy. CT
showed that the inferior vesical thickening had become
more severe, part of which was due to the presence of
an irregular-shaped mass. It had wide base and rough
surface, and the biggest plane was about 6.8 cm × 4.5
cm. The delimitation between internal urethral orifice
and the mass was not clear (Figure 5). Enlarged lymph
nodes were found in right iliac vessels and inguinal
region. Although we notified her that TUR-BT could
not cure her illness and recommended that radical
cystectomy should be done, the patient insisted upon
having TUR-BT. The pathological diagnosis was still
clear cell carcinoma.
After the second TUR-BT, the TNM stage was evalu-
ated as T2bN1M0. The patient still used mitomycin for
intravesical therapy and rejected any cystectomy, che-
motherapy and radiotherapy. Two months later, she
found vulval edema and had the urinary symptoms of
frequency, urgency and painful urination, complicated
with dysuria. Cystoscopy and CT scan both demon-
strated the carcinoma was recurrent again and that the
mass had invaded the urethra (Figure 6). We considered
it was too late to do radical cystectomy or any other
surgeries. On the patient’s strong demand, TUR-BT was
done again as a cytoreductive surgery. The pathological
diagnosis was the same as previously. After the third
TUR-BT, the urinary symptoms such as urinary fre-
quency, urgency, pain in urination and dysuria had little
relieved. Two months later, a vaginal neoplasm and
multiple cervical lymphadenectasis were found. The
TNM stage has been advanced into T4aN2bM0. Follow-
ing up 12 months after the last TUR-BT, she was still
alive but with progression of the disease.
Discussion
Primary clear cell carcinoma of the bladder is a very
rare histological and pathological type of bladder cancer.
It was first reported by Dow and Young in 1968 [5]. For
a literature review we searched relevant case reports
published in English language. To evaluate clinical char-
acteristics better, the case reports that do not have any
data about treatment and outcomes were not included.
A total of 38 case reports (the current case and 37
others) were included in the present review (Table 1)
[5-19]. Length of follow-up in these cases ranged from 8
months to 7 years.
The reported mean age at presentation was 62.2 and
the median age was 63 (range, 35-80). There were more
female cases than male (21 female vs 16 male), which
was different from TCC. The usual presenting symp-
toms included gross hematuria, dysuria, recurrent UTI
and suprapubic pain. Patients rarely complained of local
tumor effects or pain from local spread of the tumor
[6]. Based on available data, the most common locations
which tumors originated from were bladder neck and
posterior wall, with incidence 31.6% (12/38) and 26.3%
(10/38) respectively. Other common locations included
trigone, lateral wall and urethra. Unlike urothelial carci-
noma, most clear cell adenocarcinomas of bladder were
large, solitary masses forming papillary or sessile struc-
tures [15].
The histogenesis of CCA of the bladder remains con-
troversial. In the older literature, tumors in most cases
were designated “mesonephric adenocarcinoma”, but
lacking convincing evidence for a mesonephric origin
Figure 5 Three months after TUR, CT showed the tumor
recurrence at the posterior wall and bladder neck and the
border with urethral orifice was not clear.
Figure 6 Two months after second TUR, CT showed that the
tumor recurrence again at the anterior wall and the neck,
invading urethra downward.
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[20]. Some authors believe that it arises from mullerian
elements in the bladder and are histogenetically identical
to the female genital tract, because in some cases the
neoplasms have been associated with vesical endome-
triosis or have arisen in mullerian duct cysts or rem-
nants in the bladder [9,21]. This has also be considered
an explanation for the observation that female incidence
is dominant. However, a recent study presented evi-
dence for urothelial origin in most clear cell adenocarci-
nomas of urinary tract, despite the morphologic
resemblance to mullerian-derived tumors of the female
genital tract [22]. Moreover, some studies suggested that
CCA may be associated with nephrogenic adenoma
because they share some similar histological features
[23,24].
The cystoscopy was necessary for all patients who
were suspected of bladder cancer, including CCA.
Because of no specific characteristics for symptoms,
signs and accessory examinations compared with com-
mon urothelial carcinoma, clear cell adenocarcinoma
Table 1 Reported cases of clear cell adenocarcinoma of the urinary bladder
No. Age Sex Site Treatment Outcome Reference
1 43 M Right lateral wall,neck RT,TC DWD(1y) [5]
2 64 F Neck TUR,RT NA [6]
3 54 F Neck TC NED(2y) [7]
4 71 F Neck,urethra RT NED(2y) [7]
5 53 F Right ureteral orifice TC DWD(9m) [7]
6 68 F Posterior,left lateral wall PC NED(3y) [6]
7 NA NA NA TC DWD(1y) [6]
8 70 F Neck RS NED(10m) [7]
9 63 M Left lateral wall,trigone TC NED(7y) [6]
10 57 F Neck RT,TC NED(18m) [6]
11 78 F Trigone TUR NED(4y) [8]
12 61 F Posterior wall PC NED(5y) [6]
13 62 F Left ureteral orifice TUR NA [6]
14 62 F Posterior wall,trigone TC NED(2y) [6]
15 73 F Posterior,anterior wall,neck,urethra RS NA [6]
16 53 M Posterior,anterior wall TUR,RT NED [6]
17 78 F Right lateral wall,neck TUR,CT,TC NA [6]
18 72 M Trigone,posterior,left lateral wall TC,RT DWD(2y) [6]
19 35 F Posterior wall TC NA [9]
20 67 M Trigone,posterior wall TC NED(14m) [6]
21 63 M NA CT,RT DWD(18m) [7]
22 78 F NA RS NED(12m) [7]
23 50 M NA TUR,RS A,P/P(63m) [7]
24 43 M NA TUR NED(30m) [7]
25 80 M Neck,left ureteral orifice TUR,CT NED(25m) [6]
26 65 M Anterior wall TC,CT DWD(18m) [10]
27 68 F Trigone RS NA [11]
28 59 F Trigone,neck TC,CT DWD(2y) [12]
29 59 M Posterior wall RT DWD(8m) [6]
30 69 M Diverticulum,right ureteral orifice Diverticulectomy NED(1y) [13]
31 54 M Done of bladder PC DWD(6m) [14]
32 55 M Left lateral wall TUR,CT DWD(18m) [15]
33 52 F Neck TC,RT,CT NED(28m) [16]
34 68 M NA Tumor resection NA [17]
35 62 F Neck,trigone,urethra TUR,RS NED(9m) [18]
36 56 F NA RS NED(10m) [19]
37 69 M NA TUR NA [1]
38 68 F Posterior wall,neck,urethra TUR A,P/P() Current case
Abbreviations: A,P/P = alive with persistence or progression of disease; CT = chemotherapy; DWD = died with disease; NA = not available; NED = no evidence of
disease; PC = partial cystectomy; RS = radical surgery; RT = radiotherapy; TC = total cystectomy.
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was diagnosed mainly on histopathology. Microscopi-
cally, CCA is characterized by admixtures of tubular
glands, microcysts, papillae and diffuse masses. The cells
range from flat to hobnail and cuboidal with abundant,
clear and glycogen-rich cytoplasm, often with significant
nuclear atypia and mitotic activity [7,20]. Immunohisto-
chemically clear cell adenocarcinoma of the bladder is
strongly positive for CK7 and variably positive for CK20,
which is similar to typical urothelial carcinoma. CA-125
is typically positive, which is generally accepted as a
marker of mullerian differentiation [20,22].
In the literature review, initial treatment for primary
clear cell carcinoma of bladder was mainly surgical
resection. All but 5 patients were initially treated with a
surgical resection (86.8%, 33/38). The surgical resection
therapy included transurethral resection (12 patients,
31.6%), total cystectomy (11 patients, 28.9%), radical sur-
gery (5 patients, 13.1%), partial cystectomy (3 patients,
7.9%) and other surgical resection (2 patients, 5.3%; one
underwent diverticulectomy, one underwent unspecific
tumor resection).
Of the 12 patients who underwent TUR-BT for their
initial surgical treatment, 5 patients did not receive
other therapies. One of the 5 patients presented no evi-
dence of disease during 4-year follow-up period. Other
patients underwent additional radical surgery, total
cystectomy, chemotherapy and radiotherapy.
Of the 11 patients who underwent total cystectomy
for their initial surgical treatment, 7 patients did not
receive other therapies. The longest follow-up period
with no evidence of disease was 7 years. Other 4
patients underwent adjuvant chemotherapy and/or
radiotherapy, but which seems no additional effects with
2 of them died with disease in 2 years and 1 in 18
months.
Four patients underwent radiotherapy as the initial
treatment and two of them received total cystectomy
later. No effect of radiotherapy was observed because
two cases died with disease in 8 months and 1 year, the
other two alive with no evidence of disease in 18
months and 2 years [5-7]. Some patients underwent
chemotherapy (including cisplatin, doxorubicin or cyclo-
phosphamide) and/or radiotherapy (40-60 Gy total) as
the adjunvant treatment, but with uncertain effects
[5,6,15].
Adding 2 patients with initial radiotherapy, there were
totally 35 patients underwent surgical resection. At last
follow-up, a total of 17 (48.6%) patients were alive with
no evidence of disease, 8 (22.9%) patients were dead
with disease, 8 (22.9%) patients were no data available
and 2 (5.7%) patients were alive with disease. On the
basis of this review, we suggest that the recommended
initial treatment for clear cell adenocarcinoma of the
urinary bladder should be surgical removal.
The prognosis of clear cell adenocarcinoma of the
bladder remains unclear. In general, it is more malig-
nant than common urothelial carcinoma, but more
cases and longer follow-up periods are required to elu-
cidate these points. Lymph nodes and bone seem to be
the most common metastatic sites for this disease
[6,15]. In the current case, the patient was found to
have multiple cervical lymphadenectasis and suspected
lymphadenectasis around right iliac vessels and ingu-
inal regions after the initial treatment. To our knowl-
edge, the present case is the first case with CCA that
underwent repeat intravesical therapy after TUR-BT
and experienced tumor recurrences many times.
Although there is insufficient evidence to show better
prognosis of total cystectomy or radical surgery than
TUR-BT, if the tumor was recurrent after TUR-BT,
like the case in this paper, we believed the patient
should undergo total cystectomy or radical surgery.
Due to different oncologic characteristics and the
prognosis of the current case, we do not think it is
efficient to adopt intravesical therapy to treat CCA of
bladder, which is a classical post-TUR treatment for
urothelial carcinoma.
Conclusions
In conclusion, because there are no characteristic
symptoms for the clear cell adenocarcinoma of blad-
der, the diagnosis is mainly based on histopathology.
However, once the diagnosis is determined, the radi-
cal surgery should be recommended. The radiotherapy
or chemotherapy may be helpful. The post-TUR intra-
vesical therapy is of no help for preventing recur-
rence, although the TUR-BT has resected all visible
tumors and even reached to the muscular layer of the
bladder.
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